Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.

Carlsmed Announces first corra™ personalized Cervical Plating Procedure

The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo® Lumbar Bi-lateral Posterior System.